Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NM-IL-12 in Relapsed/Refractory DLBCL
NCT02544724Phase 2Unknown
- Sponsor
- Neumedicines Inc.
- Start
- Nov 2016
- Primary completion
- Aug 2017
- Modality
- Cytokines & Interferons
01
Overview
A Phase 2 trial of HemaMax in diffuse large B-cell lymphoma (DLBCL), sponsored by Neumedicines Inc.. Status: unknown.
02
Drugs
HemaMax
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT02544724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02544724.